# Kiyotaka Yoh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kiyotaka-yoh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,550 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 46 |
| i10-index | 136 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5052865562 |
| ORCID iD | 0000-0001-6928-357X |
| Works | 490 |

## Researcher papers

- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component](https://scholariq.org/papers/osimertinib-in-pretreated-t790m-positive-advanced-non-small-cell-lung-cancer/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)
- [Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial](https://scholariq.org/papers/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small/)
- [Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.](https://scholariq.org/papers/beyond-alk-ret-ros1-and-other-oncogene-fusions-in-lung-cancer/)
- [Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer](https://scholariq.org/papers/breast-cancer-resistance-protein-impacts-clinical-outcome-in-platinum-based/)
- [HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy](https://scholariq.org/papers/herthena-lung01-a-phase-ii-trial-of-patritumab-deruxtecan-her3-dxd-in-epidermal/)
- [Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis](https://scholariq.org/papers/therapeutic-priority-of-the-pi3k-akt-mtor-pathway-in-small-cell-lung-cancers-as/)
- [Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-versus-docetaxel-for-previously-treated-advanced-or/)
- [Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung](https://scholariq.org/papers/genomic-profiling-of-large-cell-neuroendocrine-carcinoma-of-the-lung/)
- [Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation](https://scholariq.org/papers/abstract-4920-a-status-of-re-biopsy-for-non-small-cell-lung-cancer-patients/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.